GHRH receptor → GH secretion → IGF-1 · Peptide
Evidence gap: Original EGRIFTA absolute SC bioavailability under 4% is an imported older-formulation finding. Do not transfer it to every formulation. Oral, intranasal and IM therapeutic PK are not established here.
Open in the interactive library →Compare with other compounds →
EGRIFTA targets excess abdominal fat in adults with HIV-associated lipodystrophy. WR and SV have different doses.
Context: Approved product labeling, specific indication.
Limitations: Formulations are not substitutable. This is not a general weight-loss or research-vial regimen.
Trials support visceral-fat reduction and liver-fat improvement in selected populations with HIV.
Context: Original formulation; HIV-associated abdominal fat / fatty liver.
Limitations: Do not generalize this population or dose to all obesity, longevity, or current formulations.
After single 1.28 mg WR SC administration in healthy subjects: median Tmax 0.15 h; mean Cmax 3831 pg/mL (CV 40%); mean AUC0-inf 1172 pg·h/mL (CV 48%); mean elimination half-life 11 min. Systemic exposure resembled older EGRIFTA 2 mg SC.
Context: DailyMed EGRIFTA WR label, sections 12.3 and 2.1; WR 11.6 mg/vial versus original EGRIFTA 1 mg/vial.
Limitations: The less-than-4% absolute SC bioavailability measurement belongs ONLY to older 1 mg/vial EGRIFTA, not WR. WR and SV cannot be substituted; oral/intranasal/IM PK not established.
Open this exact record in the library →Suggest a correctionOriginal EGRIFTA 2 mg SC daily: Study 1 VAT mean change -18% versus +2% placebo; Study 2 -14% versus -2% placebo. Mean weight differences versus placebo were small and not statistically significant in the label tables.
Context: DailyMed EGRIFTA WR label section 14, Table 2 and Table 3; original 1 mg/vial formulation; trials NCT00123253 and NCT00435136.
Limitations: These results reflect HIV-infected adults with lipodystrophy, not generalized obesity or WR-specific efficacy trials; VAT reduction does not imply substantial total weight loss.
Open this exact record in the library →Suggest a correctionIn original-formulation trials, injection-site reactions occurred in 25% versus 14% placebo, and hypersensitivity reactions in 4% of EGRIFTA recipients. Diabetes defined by HbA1c >=6.5% occurred in 5% versus 1% placebo (HR 3.3, 95% CI 1.4–9.6). Anti-tesamorelin IgG was detected in 50% after 26 weeks, 47% after 52 weeks, and in 85% of the subset with hypersensitivity reactions.
Context: DailyMed EGRIFTA WR label sections 5.4–5.6, 6.1, 12.6; safety extrapolated from original EGRIFTA (1 mg/vial). Antibody positivity is not synonymous with clinical allergy.
Limitations: Percentages are from the older EGRIFTA clinical studies, not direct WR-specific event rates or estimates for research preparations. Antibody testing depends on assay and observation time. The label also warns of elevated IGF-1, edema, glucose intolerance, neoplasm concerns and severe hypersensitivity.
Open this exact record in the library →Suggest a correctionEGRIFTA WR is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for weight-loss management. WR 11.6 mg/vial and SV 2 mg/vial differ in dose, reconstitution and storage and are not substitutable. Long-term cardiovascular safety is not established.
Context: DailyMed EGRIFTA WR label sections 1, 2.1, 4, 5 and 12.3; dosing context applies to approved product formulations.
Limitations: No verified human PK or efficacy here for oral/intranasal formulations, nontrial peptide vials, alternate cycles, or personalized allergy prevention; do not extrapolate original EGRIFTA safety rates to WR as independently measured.
Open this exact record in the library →Suggest a correctionIn a 12-month randomized study of people with HIV and fatty liver disease, tesamorelin reduced hepatic fat by approximately 37% relative to baseline.
Context: NCT02196831; 61 enrolled; randomized placebo-controlled trial; original studied formulation and HIV-specific population.
Limitations: Do not generalize to all MASLD populations or current tesamorelin formulations; no general fatty-liver indication is established by this trial.
Open this exact record in the library →Suggest a correctionThe 2007 trial randomized 412 adults with HIV and abdominal fat accumulation to original-formulation tesamorelin 2 mg SC daily or placebo for 26 weeks. VAT changed −15.2% versus +5.0%, a 20.2-percentage-point difference.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: No established general treatment protocol; retain the population, molecule and route limitations.
Open this exact record in the library →Suggest a correctionThe 2019 study enrolled 61 participants; 30 per arm received treatment. Tesamorelin 2 mg daily for 12 months produced a liver-fat treatment effect of −4.1 percentage points (approximately −37% relative). Fibrosis progression was 2/19 versus 9/24 evaluable participants.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: Small HIV/NAFLD trial; fibrosis progression is a secondary histology result, not proof of fibrosis reversal or non-HIV efficacy.
Open this exact record in the library →Suggest a correctionA 2012 trial enrolled 152 adults aged 55–87, including 66 with mild cognitive impairment; 137 completed. Tesamorelin 1 mg SC daily for 20 weeks produced an executive-function signal.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: Not established general focus enhancement, dementia prevention or benefit in younger healthy adults.
Open this exact record in the library →Suggest a correctionDistinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · Adults with HIV-associated excess abdominal fat / lipodystrophy · EGRIFTA WR
Approved product label: Amount: 1.28 mg; Frequency: Once daily; Route: SC; Species: Human; Population: Adults with HIV-associated excess abdominal fat / lipodystrophy; Formulation: EGRIFTA WR
Limitations: Formulation-specific label regimen. WR, SV, original EGRIFTA and research-vial products are not interchangeable.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · Adults with HIV-associated excess abdominal fat / lipodystrophy · EGRIFTA SV
Approved product label: Amount: 1.4 mg; Frequency: Once daily; Route: SC; Species: Human; Population: Adults with HIV-associated excess abdominal fat / lipodystrophy; Formulation: EGRIFTA SV
Limitations: Formulation-specific label regimen. WR, SV, original EGRIFTA and research-vial products are not interchangeable.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · 412 adults with HIV-associated abdominal fat accumulation · Original formulation
Human study regimen: Amount: 2 mg; Frequency: Once daily; Duration: 26 weeks; Timing: Between 6 a.m. and noon; Route: SC; Species: Human; Population: 412 adults with HIV-associated abdominal fat accumulation; Formulation: Original formulation
Limitations: Morning trial dosing does not establish bedtime superiority. This is not general weight-loss dosing.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · People with HIV and fatty liver · Original formulation
Human study regimen: Duration: 12 months; Route: Not documented; Species: Human; Population: People with HIV and fatty liver; Formulation: Original formulation
Limitations: This saved review passage records duration and outcomes but not the administered amount, frequency or route. Do not infer them from another trial.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · 152 adults aged 55–87, including mild cognitive impairment
Human study regimen: Amount: 1 mg; Frequency: Once daily; Duration: 20 weeks; Timing: 30 minutes before bedtime; Route: SC; Species: Human; Population: 152 adults aged 55–87, including mild cognitive impairment
Limitations: Preliminary executive-function finding; does not establish dementia prevention or general nootropic efficacy.
Tesamorelin-induced GH secretion can cause edema, arthralgia and carpal tunnel symptoms. Labeling advises IGF-1 and glucose monitoring; consider discontinuation for persistent IGF-1 elevations, for example >3 age-adjusted SDS, particularly without a robust efficacy response.
Context: Approved EGRIFTA WR label sections 4 and 5; safety observations derive from the original-formulation studies. The video discusses these effects at 0:51–1:22, 1:37–3:24 and 6:10–6:43.
Limitations: Active malignancy is contraindicated; prolonged IGF-1 elevation has unknown effects. Glucose intolerance/diabetes and hypersensitivity remain risks. The label does not establish edema resolution at weeks 3–4 or validate a 500 mcg titration scheme. Persistent or progressive symptoms must not be presumed an adjustment period.
Open this exact record in the library →Suggest a correctionIn a randomized trial of 404 adults with HIV and central fat accumulation, original-formulation tesamorelin was studied for six months, followed by rerandomization to continuation or placebo for six months. VAT reduction reached approximately 18% at 12 months among continuing patients; initial VAT improvements were rapidly lost after switching to placebo.
Context: Falutz et al. 2010 abstract; original EGRIFTA 2 mg SC daily. Video claim at 8:57–9:34 is supported within this population.
Limitations: HIV-associated abdominal fat accumulation; abstract-only trial review. This does not quantify regain for an individual or validate 12–16-week courses and 30-day breaks. Current approved formulations have different labeled doses.
Open this exact record in the library →Suggest a correctionAn exploratory secondary analysis found improvements in selected trunk-muscle CT density and area after 26 weeks. It compared 193 tesamorelin responders with 148 placebo participants with available scans; active participants were selected for at least 8% VAT reduction.
Context: Adults with HIV and abdominal adiposity from two prior trials. DOI 10.14283/jfa.2018.45; full text reviewed. Video 7:26–7:41 generalizes to lean muscle preservation or building.
Limitations: Responder-selected secondary analysis rather than an unselected randomized comparison. Muscle imaging does not establish strength, function, athletic hypertrophy, or muscle preservation during tirzepatide/retatrutide treatment.
Open this exact record in the library →Suggest a correctionThe major sleep-related GH peak is associated principally with deep, slow-wave sleep, not REM as asserted at 9:41–9:48. A classic physiology study sampled eight young adults over 38 nights; this was not a tesamorelin dosing study. EGRIFTA labeling specifies daily administration without a mandatory bedtime or fasting interval.
Context: General human GH physiology plus selected label administration instructions. Video 9:41–11:02 extrapolates to bedtime, fasting and sleep benefits.
Limitations: No comparative tesamorelin evidence reviewed establishes bedtime superiority, required 2–3-hour meal separation, better sleep, or extra visceral-fat loss from that window. Human physiology is not clinical validation of a timing protocol.
Open this exact record in the library →Suggest a correctionGH/IGF-1 physiology supplies a rationale, but not proof of added muscle preservation or longevity from stacking.
Context: Proposed uses beyond the studied indication.
Limitations: Separate pathways and analogies are not controlled human outcome evidence.
Hexarelin’s reduced GH response during 16-week treatment cannot establish cycling requirements for tesamorelin, CJC or ipamorelin. The article supplies no controlled evidence that its proposed GH-peptide combinations preserve skeletal muscle during GLP-1 treatment.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: No validated cycle or GLP-1 muscle-preservation regimen. Current label formulations have distinct daily doses; original trial doses are not interchangeable. IGF-1 elevation alone does not prove benefit or diagnose GH deficiency. Preserve label glucose, IGF-1, fluid-retention, malignancy and hypersensitivity precautions; endogenous GH release is not a safety guarantee.
Open this exact record in the library →Suggest a correctionDistinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Theoretical protocol proposal: Duration: Four months of mitochondrial preparation mentioned as a proposed prerequisite
Limitations: The saved review states that this is not a demonstrated prerequisite. Specific agents, dose, route and frequency for the preparation period are not defined.
At 6:43–8:21 the creator proposes tesamorelin alongside tirzepatide or retatrutide, and discusses MOTS-c/NAD+ or BPC-157/TB-500. These are proposed complementary mechanisms and personal/clinic observations, not controlled combination outcomes.
Context: Video transcript reviewed. Targeted searches did not identify controlled human evidence validating the proposed combinations or tesamorelin/ipamorelin ratios; this is a bounded search, not proof no study exists.
Limitations: Monotherapy outcomes, GH/IGF-1 biology and distinct targets cannot establish combination efficacy, interactions, muscle preservation or faster recovery. TB-500 product identity must not be conflated with full-length thymosin beta-4. No verified stack regimen is added.
Open this exact record in the library →Suggest a correctionHunter Williams favors bedtime use after food and five days on / two off; multiple longer cycles are described.
Context: Supplied video transcript, not a comparative dosing trial.
Limitations: Lower-dose equivalence, bedtime superiority, receptor resets and prevention of allergy are unproven.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Some smaller women
Attributed proposal / anecdote: Amount: 0.5 mg; Frequency: Daily, as described by the speaker; Route: Not documented; Population: Some smaller women
Limitations: Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: General optimization, as described by the speaker
Attributed proposal / anecdote: Amount: 1 mg; Route: Not documented; Population: General optimization, as described by the speaker
Limitations: Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Athletic goals, as described by the speaker
Attributed proposal / anecdote: Amount: 1–1.5 mg; Route: Not documented; Population: Athletic goals, as described by the speaker
Limitations: Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Greater visceral-fat goals, as described by the speaker
Attributed proposal / anecdote: Amount: 2 mg; Route: Not documented; Population: Greater visceral-fat goals, as described by the speaker
Limitations: Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Timing: Bedtime, one to two hours after food; morning if sleep is disturbed; sometimes divides the daily amount; Route: Not documented
Limitations: No split ratio is provided. Fasting, bedtime and divided administration are not established as clinically superior.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Frequency: Five days on / two days off; Route: Not documented
Limitations: No receptor-reset requirement or equivalent efficacy versus daily labeling has been demonstrated.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Duration: 8 weeks on / 4 weeks off; Route: Not documented
Limitations: Proposed coaching cycle; dose, route and per-week frequency are not supplied for this specific cycle. Do not automatically assemble separate suggestions into one regimen.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Duration: 12 weeks on / 4 weeks off; Route: Not documented
Limitations: Proposed coaching cycle; dose, route and per-week frequency are not supplied for this specific cycle. Do not automatically assemble separate suggestions into one regimen.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Duration: 16–24 weeks on / 8–12 weeks off; Route: Not documented
Limitations: Proposed coaching cycle; dose, route and per-week frequency are not supplied for this specific cycle. Do not automatically assemble separate suggestions into one regimen.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Duration: Longer liver-fat courses followed by breaks; exact course and break durations not specified; Route: Not documented
Limitations: Not an established requirement, and not a substitute for the trial’s actual methods.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Proposed combination; product formulation unspecified
Attributed proposal / anecdote: Amount: Approximately 600 mcg tesamorelin + 200 mcg ipamorelin; Route: Not documented; Formulation: Proposed combination; product formulation unspecified
Limitations: Dose attribution only. Frequency, route and duration are not supplied for this combination passage. Equivalence to HGH, muscle superiority and safety are unproven.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Amount: 0.5–1 mg; Frequency: Five days on / two days off; Timing: Before bed, away from meals; Route: Not documented; Sequence: After at least two to four weeks or longer on retatrutide
Limitations: Clinic proposal, not a controlled combination regimen. Route is not explicitly specified in the saved protocol passage.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Route: Not documented; Sequence: Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns
Limitations: No amount, duration, route, phase interval or CJC DAC status is supplied. Association with this no-DAC listing does not establish that the video used no-DAC.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Route: IM; Sequence: Speaker suggests changing to IM in response to welts or hives; no dose, schedule or clinical validation supplied
Limitations: Unsupported route suggestion, not an instruction. Changing route does not remove systemic allergy risk; the saved label review directs discontinuation for hypersensitivity and clinical assessment.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Amount: 2 mg; Frequency: 5 days on and 2 days off; Duration: 10–12 weeks, then 4–6 weeks off; Timing: Bedtime or fasted morning; Route: Not documented
Limitations: Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Duration: 12 weeks tesamorelin, 4 weeks off, then 12 weeks CJC no DAC plus ipamorelin; Route: Not documented
Limitations: Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.
The creator describes starting around 500 mcg tesamorelin for several weeks; approximately 1 mg tesamorelin with 300 mcg ipamorelin, or 200–300 mcg ipamorelin alongside higher tesamorelin; five-on/two-off or six-on/one-off schedules; and 12–16-week courses followed by 30 days off.
Context: Source observations at 2:25–4:26 and 4:34–6:10. No tested population, standardized formulation or validated administration route supplied for these examples. Creator acknowledges these are not FDA schedules.
Limitations: Anecdotal source record only, not a treatment recommendation or evidence of safe ratios, equivalent efficacy, reduced adverse effects, desensitization prevention or receptor resetting. No steroid-style post-cycle therapy is specified in labeling, but this does not validate arbitrary stop/start cycles.
Open this exact record in the library →Suggest a correctionVisible effects usually emerge at weeks 3–8
Context: Owner-approved social research lead; not independently substantiated.
Limitations: Clinical trial outcomes do not validate universal individualized timeline
Open this exact record in the library →Suggest a correctionThese compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.